Stephen Chin1, Abiola Fatimilehin2, Richard Walshaw3, Arjun Argarwal2, Hitesh Mistry4, Tony Elliott2, John Logue2, James Wylie2, Ananya Choudhury5. 1. Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Rural Clinical School, University of New South Wales, Coffs Harbour, New South Wales, Australia. 2. Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom. 3. Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom. 4. Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom; Division of Pharmacy, The University of Manchester, Manchester, United Kingdom. 5. Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom. Electronic address: ananya.choudhury@christie.nhs.uk.
Abstract
PURPOSE: Although high-level evidence supports moderately hypofractionated radiation therapy for definitive prostate treatment, there is less evidence for its use in the postprostatectomy setting. We externally validated a contemporary nomogram predicting biochemical failure (BF) after salvage radiation therapy (SRT) and report long-term disease control outcomes for hypofractionated SRT to the prostate bed. METHODS AND MATERIALS: A retrospective review was performed for 112 patients treated with hypofractionated SRT (52.5 Gy in 20 fractions using 3-dimensional conformal radiation therapy) for pT2-4R0-1N0/XM0 prostate adenocarcinoma, with postoperative prostate-specific antigen (PSA) greater than 0.1 ng/mL or rising. Freedom from BF (FFBF), distant metastasis, cancer-specific mortality, and overall survival were analyzed from commencement of radiation therapy. Cox regression was performed on FFBF to account for covariates. BF was defined as a PSA ≥0.4 ng/mL and rising after SRT. Early SRT was defined as SRT commencing at a pre-SRT PSA of ≤0.2 ng/mL. RESULTS: Median follow-up was 10.0 years (interquartile range, 9.3-10.7 years), median pre-SRT PSA was 0.4 ng/mL, and androgen deprivation therapy was used in 14% of patients. The 5/10-year FFBF, distant metastasis, cancer-specific mortality, and overall survival were 68%/51%, 7%/16%, 5%/11%, and 90%/75%, respectively. FFBF for early SRT compared with late SRT was 81% versus 66% at 5 years and 68% versus 49% at 10 years. On multivariable analysis, pre-SRT PSA, International Society of Urologic Pathology grade group, seminal vesicle invasion, and androgen deprivation therapy use were associated with FFBF. The nomogram c-index was 0.67, and it overestimated FFBF by 10% and 15% at 5 and 10 years, respectively, with confidence intervals overlapping the line of unity. CONCLUSIONS: Hypofractionated SRT provides long-term disease control outcomes comparable to conventionally fractionated radiation therapy. Early SRT provides improved disease control, with two-thirds of patients with pre-SRT PSA of ≤0.2 ng/mL free of BF at 10 years. We performed the first external validation of the Tendulkar salvage nomogram, which showed a robust model performance.
PURPOSE: Although high-level evidence supports moderately hypofractionated radiation therapy for definitive prostate treatment, there is less evidence for its use in the postprostatectomy setting. We externally validated a contemporary nomogram predicting biochemical failure (BF) after salvage radiation therapy (SRT) and report long-term disease control outcomes for hypofractionated SRT to the prostate bed. METHODS AND MATERIALS: A retrospective review was performed for 112 patients treated with hypofractionated SRT (52.5 Gy in 20 fractions using 3-dimensional conformal radiation therapy) for pT2-4R0-1N0/XM0 prostate adenocarcinoma, with postoperative prostate-specific antigen (PSA) greater than 0.1 ng/mL or rising. Freedom from BF (FFBF), distant metastasis, cancer-specific mortality, and overall survival were analyzed from commencement of radiation therapy. Cox regression was performed on FFBF to account for covariates. BF was defined as a PSA ≥0.4 ng/mL and rising after SRT. Early SRT was defined as SRT commencing at a pre-SRT PSA of ≤0.2 ng/mL. RESULTS: Median follow-up was 10.0 years (interquartile range, 9.3-10.7 years), median pre-SRT PSA was 0.4 ng/mL, and androgen deprivation therapy was used in 14% of patients. The 5/10-year FFBF, distant metastasis, cancer-specific mortality, and overall survival were 68%/51%, 7%/16%, 5%/11%, and 90%/75%, respectively. FFBF for early SRT compared with late SRT was 81% versus 66% at 5 years and 68% versus 49% at 10 years. On multivariable analysis, pre-SRT PSA, International Society of Urologic Pathology grade group, seminal vesicle invasion, and androgen deprivation therapy use were associated with FFBF. The nomogram c-index was 0.67, and it overestimated FFBF by 10% and 15% at 5 and 10 years, respectively, with confidence intervals overlapping the line of unity. CONCLUSIONS: Hypofractionated SRT provides long-term disease control outcomes comparable to conventionally fractionated radiation therapy. Early SRT provides improved disease control, with two-thirds of patients with pre-SRT PSA of ≤0.2 ng/mL free of BF at 10 years. We performed the first external validation of the Tendulkar salvage nomogram, which showed a robust model performance.
Authors: Nicholas G Zaorsky; James B Yu; Sean M McBride; Robert T Dess; William C Jackson; Brandon A Mahal; Ronald Chen; Ananya Choudhury; Ann Henry; Isabel Syndikus; Timur Mitin; Alison Tree; Amar U Kishan; Daniel E Spratt Journal: Adv Radiat Oncol Date: 2020-10-29
Authors: Richard Simcock; Toms Vengaloor Thomas; Christopher Estes; Andrea R Filippi; Matthew A Katz; Ian J Pereira; Hina Saeed Journal: Clin Transl Radiat Oncol Date: 2020-03-24
Authors: Christina Schröder; Hongjian Tang; Paul Windisch; Daniel Rudolf Zwahlen; André Buchali; Erwin Vu; Tilman Bostel; Tanja Sprave; Thomas Zilli; Vedang Murthy; Robert Förster Journal: Cancers (Basel) Date: 2022-01-29 Impact factor: 6.639
Authors: Nicholas G Zaorsky; James B Yu; Sean M McBride; Robert T Dess; William C Jackson; Brandon A Mahal; Ronald Chen; Ananya Choudhury; Ann Henry; Isabel Syndikus; Timur Mitin; Alison Tree; Amar U Kishan; Daniel E Spratt Journal: Adv Radiat Oncol Date: 2020-04-01
Authors: David J Thomson; Sue S Yom; Hina Saeed; Issam El Naqa; Leslie Ballas; Soren M Bentzen; Samuel T Chao; Ananya Choudhury; Charlotte E Coles; Laura Dover; B Ashleigh Guadagnolo; Matthias Guckenberger; Peter Hoskin; Salma K Jabbour; Matthew S Katz; Somnath Mukherjee; Agata Rembielak; David Sebag-Montefiore; David J Sher; Stephanie A Terezakis; Toms V Thomas; Jennifer Vogel; Christopher Estes Journal: Int J Radiat Oncol Biol Phys Date: 2020-08-11 Impact factor: 7.038